Skip to main content

Does #Neanderthal #DNA increase the #risk for severe #COVD-19 ?

The Neanderthal genome project is an effort of a group of scientists to sequence the Neanderthal genome, founded in July 2006.

It was initiated by 454 Life Sciences, a biotechnology company based in Branford, Connecticut in the United States and is coordinated by the Max Planck Institute for Evolutionary Anthropology in Germany. In May 2010 the project published their initial draft of the Neanderthal genome based on the analysis of four billion base remain in modern humans outside Africa.

In December 2013, a high coverage genome of a Neanderthal was reported for the first time. It stemmed from a Neanderthal female bone fragment found in a cave in the Altai mountains of Siberia from around 50,000–100,000 years ago.

As per the press release from Max Planck Institute for Evolutionary Anthropology. - 'A segment of DNA that causes their carriers to have an up to three times higher risk of developing severe Covid-19 is inherited from Neandertals.'

'Covid-19 affects some people much more severely than others. Some reasons for this such as old age are already known, but other as yet unknown factors also play a role. This summer, a large international study linked a group of genes on chromosome 3 to a higher risk of hospitalisation and respiratory failure upon infection with the Sars-CoV-2 virus. Researchers at the Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Germany have now analysed the gene cluster.'



Share this trusted information.

Comments

Popular posts from this blog

#COVID-19 #Vaccines and #Vaccination

  Key Points Available evidence suggests the currently authorized mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) provide protection against a variety of strains, including B.1.1.7 (originally identified in the United Kingdom) and B.1.351 (originally identified in South Africa). Other vaccines show reduced efficacy against B.1.351 but may still protect against severe disease. Continued monitoring of vaccine effectiveness against variants is needed. A growing body of evidence indicates that people fully vaccinated with an mRNA vaccine (Pfizer-BioNTech and Moderna) are less likely to have asymptomatic infection or to transmit SARS-CoV-2 to others. Studies are underway to learn more about the benefits of Johnson & Johnson/Janssen vaccine. However, the risk for SARS-CoV-2 infection in fully vaccinated people cannot be completely eliminated as long as there is continued community transmission of the virus. At this time, there are limited data on vaccine effectiveness in people who

Frequently Asked Questions about #COVID-19 #Vaccination

If I have already had COVID-19 and recovered, do I still need to get vaccinated with a COVID-19 vaccine? Yes, you should be vaccinated regardless of whether you already had COVID-19. That’s because experts do not yet know how long you are protected from getting sick again after recovering from COVID-19. Even if you have already recovered from COVID-19, it is possible—although rare—that you could be infected with the virus that causes COVID-19 again. Studies have shown that vaccination provides a strong boost in protection in people who have recovered from COVID-19. Learn more about why getting vaccinated is a safer way to build protection than getting infected. If you were treated for COVID-19 with monoclonal antibodies or convalescent plasma, you should wait 90 days before getting a COVID-19 vaccine. Talk to your doctor if you are unsure what treatments you received or if you have more questions about getting a COVID-19 vaccine. If you or your child has a history of multisystem inflam

COVID 19 - Delta and Delta Plus Variant

SARS-CoV-2 Delta variant, also known as lineage B.1.617.2, is a variant of lineage B.1.617 of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India in late 2020. The World Health Organization (WHO) named it the Delta variant on 31 May 2021. It has mutations in the gene encoding the SARS-CoV-2 spike protein causing the substitutions T478K, P681R and L452R, which are known to affect the transmissibility of the virus as well as whether it can be neutralised by antibodies for previously circulating variants of the COVID-19 virus. Public Health England (PHE) in May 2021 observed secondary attack rates to be 51–67% higher than the alpha variant. On 7 May 2021, PHE changed their classification of lineage B.1.617.2 from a variant under investigation (VUI) to a variant of concern (VOC) based on an assessment of transmissibility being at least equivalent to B.1.1.7 (Alpha variant); the UK's SAGE subsequently estimated a "realistic" possibility of being 50% mor